Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Strong-Buy at Wall Street Zen

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report issued on Saturday. A number of other analysts have also recently issued reports on the company. Barclays lifted their price objective on Alnylam Pharmaceuticals from $329.00 to $460.00 […]

Leave a Reply

Your email address will not be published.

Previous post Jamie Oliver and wife take £2.5m dividend despite profits slump at chef’s restaurant and media empire
Next post Global X Clean Water ETF (NASDAQ:AQWA) Sees Significant Decline in Short Interest